KRAS mutation is an early oncogenic event in PC because it is detectable in up to 38% of premalignant pancreatic lesions, indicating that KRAS mutation is likely an early and initiating event in PC [9]. The gene discussed is KRAS; the disease is pachyonychia congenita.